249 related articles for article (PubMed ID: 23122859)
1. Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors.
Oka Y; Yabuuchi T; Fujii Y; Ohtake H; Wakahara S; Matsumoto K; Endo M; Tamura Y; Sekiguchi Y
Bioorg Med Chem Lett; 2012 Dec; 22(24):7534-8. PubMed ID: 23122859
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-{5-[3-(3-hydroxypiperidin-1-yl)-1,2,4-oxadiazol-5-yl]-4-methyl-1,3-thiazol-2-yl}acetamide (TASP0415914) as an orally potent phosphoinositide 3-kinase γ inhibitor for the treatment of inflammatory diseases.
Oka Y; Yabuuchi T; Oi T; Kuroda S; Fujii Y; Ohtake H; Inoue T; Wakahara S; Kimura K; Fujita K; Endo M; Taguchi K; Sekiguchi Y
Bioorg Med Chem; 2013 Dec; 21(24):7578-83. PubMed ID: 24262886
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
[TBL] [Abstract][Full Text] [Related]
5. 5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors.
Gentile G; Merlo G; Pozzan A; Bernasconi G; Bax B; Bamborough P; Bridges A; Carter P; Neu M; Yao G; Brough C; Cutler G; Coffin A; Belyanskaya S
Bioorg Med Chem Lett; 2012 Mar; 22(5):1989-94. PubMed ID: 22310227
[TBL] [Abstract][Full Text] [Related]
6. Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
Epple R; Cow C; Xie Y; Azimioara M; Russo R; Wang X; Wityak J; Karanewsky DS; Tuntland T; Nguyêñ-Trân VT; Cuc Ngo C; Huang D; Saez E; Spalding T; Gerken A; Iskandar M; Seidel HM; Tian SS
J Med Chem; 2010 Jan; 53(1):77-105. PubMed ID: 19928766
[TBL] [Abstract][Full Text] [Related]
7. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel series of 4-quinolone JNK inhibitors.
Gong L; Tan YC; Boice G; Abbot S; McCaleb K; Iyer P; Zuo F; Dal Porto J; Wong B; Jin S; Chang A; Tran P; Hsieh G; Niu L; Shao A; Reuter D; Lukacs CM; Ursula Kammlott R; Kuglstatter A; Goldstein D
Bioorg Med Chem Lett; 2012 Dec; 22(24):7381-7. PubMed ID: 23142618
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
He L; Seitz SP; Trainor GL; Tortolani D; Vaccaro W; Poss M; Tarby CM; Tokarski JS; Penhallow B; Hung CY; Attar R; Lin TA
Bioorg Med Chem Lett; 2012 Sep; 22(18):5995-8. PubMed ID: 22902653
[TBL] [Abstract][Full Text] [Related]
10. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
Terao Y; Suzuki H; Yoshikawa M; Yashiro H; Takekawa S; Fujitani Y; Okada K; Inoue Y; Yamamoto Y; Nakagawa H; Yao S; Kawamoto T; Uchikawa O
Bioorg Med Chem Lett; 2012 Dec; 22(24):7326-9. PubMed ID: 23147077
[TBL] [Abstract][Full Text] [Related]
11. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG
Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ.
Collier PN; Martinez-Botella G; Cornebise M; Cottrell KM; Doran JD; Griffith JP; Mahajan S; Maltais F; Moody CS; Huck EP; Wang T; Aronov AM
J Med Chem; 2015 Jan; 58(1):517-21. PubMed ID: 24754609
[TBL] [Abstract][Full Text] [Related]
13. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
[TBL] [Abstract][Full Text] [Related]
14. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors.
Yun W; Ahmad M; Chen Y; Gillespie P; Conde-Knape K; Kazmer S; Li S; Qian Y; Taub R; Wertheimer SJ; Whittard T; Bolin D
Bioorg Med Chem Lett; 2011 Dec; 21(23):7205-9. PubMed ID: 22001092
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL
Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization.
Yang LL; Li GB; Yan HX; Sun QZ; Ma S; Ji P; Wang ZR; Feng S; Zou J; Yang SY
Eur J Med Chem; 2012 Oct; 56():30-8. PubMed ID: 22944772
[TBL] [Abstract][Full Text] [Related]
20. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
Furet P; Guagnano V; Fairhurst RA; Imbach-Weese P; Bruce I; Knapp M; Fritsch C; Blasco F; Blanz J; Aichholz R; Hamon J; Fabbro D; Caravatti G
Bioorg Med Chem Lett; 2013 Jul; 23(13):3741-8. PubMed ID: 23726034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
